Comparative Pharmacology
Head-to-head clinical analysis: GVS versus TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0 9 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GVS versus TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0 9 IN PLASTIC CONTAINER.
GVS vs TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GVS is not a recognized drug. No mechanism of action available.
Tobramycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting protein synthesis in susceptible bacteria.
1 mg IV bolus every 3 minutes up to 3 doses as needed for status epilepticus; max total dose 3 mg.
3-5 mg/kg/day IV divided every 8 hours or 5-7 mg/kg IV once daily for adults with normal renal function.
None Documented
None Documented
Terminal half-life: 3-5 hours in healthy adults; prolonged to 8-12 hours in severe renal impairment (CrCl <30 mL/min).
2-3 hours in patients with normal renal function; prolonged to 24-60 hours in anuria. Half-life is directly correlated with creatinine clearance.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other.
Primarily renal (glomerular filtration) with >90% excreted unchanged in urine within 24 hours; minimal biliary/fecal (<1%).
Category C
Category D/X
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic